Supporting Information (SI)

## Three Peroxidovanadium(V) Compounds Mediated by Transition Metal

## **Cations for Enhanced Anticancer Activity**

Fanghui Chen,‡<sup>a</sup> Zhiguo Gao,‡<sup>a</sup> Chaoqun You,<sup>b</sup> Hongshuai Wu,<sup>a</sup> Yaojia Li,<sup>a</sup> Xiaotong He,<sup>a</sup> Yuchen Zhang,<sup>a</sup> Yaan Zhang,<sup>c</sup> Baiwang Sun<sup>\*,a</sup>

<sup>a</sup> School of Chemistry and Chemical Engineering, Southeast University, Nanjing 210089, PR China. Fax: +86 25 52090614, Tel: +86 25 52090614, E-mail address: chmsunbw@seu.edu.cn

<sup>b</sup> College of Chemical Engineering, Nanjing Forestry University, Nanjing 210037, PR China

<sup>c</sup> School of Pharmaceutical and Chemical Engineering, Chengxian College, Southeast University, Nanjing, Jiangsu Province, 210088, PR China

‡ These authors have contributed equally to the work.

Crystal	V1	V2	V3	
Formula	C <sub>6</sub> H <sub>13</sub> KNO <sub>9</sub> V	$C_6H_{12}KN_2O_8V$	C <sub>6</sub> H <sub>8</sub> KN <sub>2</sub> O <sub>9</sub> V	
Formula weight	333.21	329.97	342.18	
Crystal size	0 12.0 12.0 11	0 12.0 12.0 11	0 20 0 20 0 10	
[mm³]	0.13×0.12×0.11	0.13×0.12×0.11	0.20×0.20×0.10	
Temperature	202(2)	100(10)	202(2)	
[κ]	293(2)	100(10)	295(2)	
Crystal system	orthorhombic	monoclinic	monoclinic	
Space group	Pbca	P21/m	P21/c	
a [Å]	15.149(4)	7.036(5)	21.717(4)	
b [Å]	7.717(2)	5.877(5)	7.836(16)	
c [Å]	18.928(7)	12.660(9)	15.792(3)	
α[°]	90	90	90	
β[°]	90	90.168(7)	108.90(3)	
γ[°]	90	90	90	
V [ų]	2212.8(12)	523.52(7)	2542.5(10)	
Z	8	2	4	
μ [mm <sup>-1</sup> ]	1.316	1.423	1.150	
F (000)	1360	440	1380	
T <sub>min</sub> ; T <sub>max</sub>	0.843; 0.865	0.831; 0.855	0.803;0.894	
Collected	ECE7	0277	1677	
reflections	5057	9277	4077	
<b>R</b> <sub>int</sub>	0.1162	0.0635	0.0556	
Obs.				
Reflections	1941	1475	4677	
[/≥2σ(/)]				
No. refined	164	120	242	
parameters	104	155	545	
wR <sub>2</sub> (all data)	0.1909	0.1987	0.2037	
R₁[/≥2σ(/)]	0.0801	0.0765	0.0753	
GooF on <i>F</i> <sup>2</sup>	1.032	1.200	1.068	
CCDC	1855753	1855754	1855755	

**Table S1.** Crystallographic Data for  $K[VO(O_2)(tricine)] \cdot H_2O(V1)$ ,  $K[VO(O_2)(edda)] \cdot H_2O(V2)$ , and  $KO[VO(O_2)(aoida)](V3)$ 

	V1		V2		V3
V1-06	1.886(5)	V1-06	1.901(6)	V1-04	1.843(5)
V1-07	1.918(6)	V1-01	1.919(5)	V1-05	1.866(6)
06-07	1.437(8)	01-06	1.446(4)	04-05	1.417(3)
V1-08	1.609(5)	V1-02	1.605(4)	V1-01	1.604(5)
06-V1-07	44.40(2)	01-V1-06	44.46(2)	04-V1-05	44.90(2)
V1-06-07	69.00(3)	V1-06-01	68.43(3)	V1-04-05	68.39(3)
V1-07-06	66.60(3)	V1-01-06	67.11(3)	V1-05-04	66.71(3)
O6-V1-O8	102.35(3)	01-V1-02	103.26(3)	01-V1-04	104.32(3)
07-V1-08	98.12(3)	02-V1-06	91.77(3)	01-V1-05	104.27(3)

**Table S2.** Selected Bond Lengths (Å) and Angles (deg) for  $K[VO(O_2)(tricine)] \cdot H_2O$  (V1), $K[VO(O_2)(edda)] \cdot H_2O$  (V2), and  $KO[VO(O_2)(aoida)]$  (V3)

**Table S3.** In vitro cytotoxicity compound **V1-V3** with or without the mediation of  $Mn^{2+}$  or Fe<sup>2+</sup> toward MCF-7, A549 and BEAS-2B cells for 24h.

Compoun	Cytotoxicity in d	653				
d	MCF-7	A549	BEAS-2B	SF		
V1	18.7 ± 0.92	16.5 ± 0.82	39.2 ± 2.9	2.10		
V1+Mn <sup>2+</sup>	5.22 ± 0.25	8.27 ± 0.42	30.3 ± 1.9	5.80		
V1+Fe <sup>2+</sup>	10.3 ± 0.53	11.3 ± 0.58	32.4 ± 2.0	3.14		
V2	29.8 ± 1.8	34.6 ± 2.4	48.1 ± 4.0	1.61		
V2+Mn <sup>2+</sup>	14.1 ± 0.65	20.6 ± 1.1	33.7 ± 2.3	2.40		
V2+Fe <sup>2+</sup>	24.2 ± 1.2	34.2 ± 2.1	38.5 ± 3.5	1.60		
V3	5.17 ± 0.27	12.9 ± 0.65	38.9 ± 3.6	7.52		
V3+Mn <sup>2+</sup>	2.23 ± 0.11	4.56 ± 0.23	30.2 ± 1.9	13.5		
V3+Fe <sup>2+</sup>	2.91 ± 0.15	4.72 ± 0.24	32.0 ± 2.0	11.0		
<sup>a</sup> SF (Selectivity Factor) is defined as $IC_{50}$ in BEAS-2B/IC <sub>50</sub> in MCF-7.						



Fig. S1 Cell viabilities of MCF-7 cells at different Mn<sup>2+</sup> concentrations for 24 h.



Fig. S2 Cell viabilities of MCF-7 cells at different Fe<sup>2+</sup> concentrations for 24 h.



**Fig. S3** Flow cytometry analysis for cell cycle distribution of MCF-7 cells induced by different reagents for 24 h. Cell staining: PI.



**Fig. S4** Flow cytometry detection intracellular ROS levels by DCFH-DA staining after 4 h of co-incubation with  $Mn^{2+}$  and different concentrations of compounds **V1** for MCF-7 cells. (p values: \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001)



**Fig. S5** Flow cytometry detection intracellular ROS levels by DCFH-DA staining after 4 h of co-incubation with  $Mn^{2+}$  and different concentrations of compound **V2** for MCF-7 cells. (p values: \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001)



**Fig. S6** Flow cytometry detection intracellular ROS levels by DCFH-DA staining after 4 h of co-incubation with  $Mn^{2+}$  and different concentrations of compound **V3** for MCF-7 cells. (p values: \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001)



Fig. S7 LC-MS spectra of compound V3 (1).



Fig. S8 LC-MS spectra of compound V3 (1) mediated by Mn<sup>2+</sup>.



Fig. S9 LC-MS spectra of compound V3 (1) mediated by Fe<sup>2+</sup>.